• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CYAN

    Cyanotech Corporation

    Subscribe to $CYAN
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.

    IPO Year:

    Exchange: NASDAQ

    Website: cyanotech.com

    Recent Analyst Ratings for Cyanotech Corporation

    DatePrice TargetRatingAnalyst
    See more ratings

    Cyanotech Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/3/24 3:27:06 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/1/24 4:42:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/27/24 1:33:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,500 worth of Cyanotech Corporation Common Stock (10,000 units at $0.75) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/25/24 4:46:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,550 worth of Cyanotech Corporation Common Stock (10,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/23/24 2:57:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,580 worth of Cyanotech Corporation Common Stock (10,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/19/24 5:01:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $8,200 worth of Cyanotech Corporation Common Stock (10,000 units at $0.82) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/17/24 4:20:44 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $8,300 worth of Cyanotech Corporation Common Stock (10,000 units at $0.83) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/13/24 4:12:42 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $8,350 worth of Cyanotech Corporation Common Stock (10,000 units at $0.83) and was granted 66,667 units of Cyanotech Corporation Common Stock (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/11/24 5:49:22 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $8,400 worth of Cyanotech Corporation Common Stock (10,000 units at $0.84) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/9/24 3:47:29 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    Cyanotech Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by VP of Sales Brand Jennifer Kimberly

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:06:36 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, HR, Secretary Nordin Amy Beth

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:04:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, Operations Jensen Glenn

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:02:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Brand Jennifer Kimberly

      3 - CYANOTECH CORP (0000768408) (Issuer)

      5/20/25 3:31:26 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Strategic Comml Officer Kakuk Collette Nicole converted options into 33 shares and covered exercise/tax liability with 14 shares, increasing direct ownership by 0.41% to 4,707 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 5:01:55 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • VP, HR, Secretary Nordin Amy Beth converted options into 33 shares and covered exercise/tax liability with 12 shares, increasing direct ownership by 0.26% to 8,074 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 4:29:57 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • VP, Quality, Regulatory & Govt Johansen Jennifer M. converted options into 33 shares and covered exercise/tax liability with 13 shares, increasing direct ownership by 0.23% to 8,881 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 4:21:04 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • VP, Operations Jensen Glenn converted options into 33 shares and covered exercise/tax liability with 13 shares, increasing direct ownership by 0.08% to 26,085 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 4:12:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • President and CEO Custer Matthew Keith converted options into 33 shares, increasing direct ownership by 0.71% to 4,679 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 4:01:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Scientific Officer Cysewski Gerald R converted options into 33 shares and covered exercise/tax liability with 13 shares, increasing direct ownership by 0.01% to 145,712 units (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      4/9/25 3:51:29 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    Cyanotech Corporation SEC Filings

    See more
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      5/8/25 3:56:11 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      2/11/25 4:01:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      12/16/24 1:53:10 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      11/12/24 4:01:40 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events

      8-K - CYANOTECH CORP (0000768408) (Filer)

      8/23/24 2:18:44 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      8/13/24 4:23:27 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      8/7/24 4:01:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Cyanotech Corporation

      DEF 14A - CYANOTECH CORP (0000768408) (Filer)

      7/11/24 6:05:39 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form ARS filed by Cyanotech Corporation

      ARS - CYANOTECH CORP (0000768408) (Filer)

      7/11/24 6:09:08 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PRE 14A filed by Cyanotech Corporation

      PRE 14A - CYANOTECH CORP (0000768408) (Filer)

      6/28/24 1:40:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    Cyanotech Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2024

      Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe

      6/26/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Format

      The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, multifunctional benefits and a 40-year legacy of farm-direct transparency and traceability. Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving. At the forefront of natural microalgae innovation, Nutrex-Hawaii addresses the evolving preferences of today's discerning consumers with its new gummies, offering a ho

      3/28/24 6:05:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2024, ended December 31, 2023. Commenting on the third quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The macroeconomic environment led to lower sales across the portfolio on a year-to-date basis, being driven particularly by Spirulina bulk sales. Industry data shows consumers are not pulling back from dietary supplements, but they have begun trading down to private label brands to save on c

      2/8/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2024, ended September 30, 2023. Commenting on the second quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The sales in the quarter are trending in the right direction with a 23.1% increase versus prior year. We generated cash flow from operations in the quarter of $0.8 million as we manage our spend in line with customer demand." "We continue to focus on driving demand in the naturally deriv

      11/8/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023. Commenting on the first quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter we continue to see the impact of consumers shifting their spend from goods to experiences and services and reallocation of spending related to the high cost of living. Due to these shifting consumer trends, we have added a new position to the Company, Chief Strategic and Commercial Officer, to oversee an

      8/11/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2023

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023. Commenting on the fiscal year results (changes shown vs. fiscal 2022), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal year 2023 was a challenging year as a result of a number of macroeconomic events and timing of sales. Consumers shifted their spend from goods to experiences and services. Lower sales in the bulk business were due in part to inventory adjustments after the global supply chain issues eased and l

      6/27/23 5:00:00 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    Cyanotech Corporation Leadership Updates

    Live Leadership Updates

    See more

    Cyanotech Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      10/3/24 6:39:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/12/24 12:25:52 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/6/24 12:45:58 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      8/15/24 7:02:20 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      7/26/24 3:04:53 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Cyanotech Corporation (Amendment)

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      12/20/23 12:07:46 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Cyanotech Corporation (Amendment)

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      8/30/23 11:36:08 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Cyanotech Corporation (Amendment)

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      8/29/23 4:45:21 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Cyanotech Corporation

      SC 13D - CYANOTECH CORP (0000768408) (Subject)

      8/29/23 4:32:25 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CYANOTECH CORP (0000768408) (Subject)

      3/10/21 11:15:27 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    Cyanotech Corporation Financials

    Live finance-specific insights

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2024

      Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe

      6/26/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2024, ended December 31, 2023. Commenting on the third quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The macroeconomic environment led to lower sales across the portfolio on a year-to-date basis, being driven particularly by Spirulina bulk sales. Industry data shows consumers are not pulling back from dietary supplements, but they have begun trading down to private label brands to save on c

      2/8/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2024, ended September 30, 2023. Commenting on the second quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The sales in the quarter are trending in the right direction with a 23.1% increase versus prior year. We generated cash flow from operations in the quarter of $0.8 million as we manage our spend in line with customer demand." "We continue to focus on driving demand in the naturally deriv

      11/8/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2024

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023. Commenting on the first quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter we continue to see the impact of consumers shifting their spend from goods to experiences and services and reallocation of spending related to the high cost of living. Due to these shifting consumer trends, we have added a new position to the Company, Chief Strategic and Commercial Officer, to oversee an

      8/11/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2023

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023. Commenting on the fiscal year results (changes shown vs. fiscal 2022), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal year 2023 was a challenging year as a result of a number of macroeconomic events and timing of sales. Consumers shifted their spend from goods to experiences and services. Lower sales in the bulk business were due in part to inventory adjustments after the global supply chain issues eased and l

      6/27/23 5:00:00 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2023

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2023, ended December 31, 2022. Commenting on the third quarter fiscal year 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Sales in the third quarter improved by $712,000, or 14%, compared to the second quarter, as we saw modest improvement in consumer movement on both finished goods and bulk sales. However, both of our online finished good sales and our international bulk sales are still not performing to histori

      2/9/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2023

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2023, ended September 30, 2022. Commenting on the second quarter fiscal 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The financial results for the quarter, compared to the same period last year, had net sales decrease driven by a confluence of events, including the increased U.S. dollar exchange rate affecting international sales, lower sales in the bulk business, primarily in Asia, due in part to inventory adj

      11/9/22 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care